Your fact-checks will appear here
British multinational pharmaceutical and biotechnology company
The 2025–2026 Northern Hemisphere flu vaccines are trivalent and chosen to target one H1N1 A strain, one H3N2 A strain, and one B/Victoria-lineage strain; U.S. regulators (FDA/CDC) recommended these c...
Three distinct RSV vaccines authorized in recent years use different active ingredients: protein-based “prefusion F” antigens in Pfizer’s ABRYSVO and GSK’s AREXVY, and a nucleoside‑modified mRNA encod...
Two widely discussed squalene-containing adjuvants used with influenza vaccines are MF59 and AS03; MF59 is the adjuvant in Fluad, an FDA‑licensed vaccine for adults ≥65, while AS03 and AF03 are other ...
Bill Gates has made personal investments aimed at Alzheimer’s research totaling about $100 million — a $50 million check to the Dementia Discovery Fund (DDF) and roughly $50 million pledged for start‑...
Major vaccine-makers show wide variation in margins driven by product mix (high-margin biologics/vaccines vs. pandemic-era COVID shots), inventory charges and one‑off items: Pfizer’s recent adjusted o...
Manufacturer copay cards frequently apply to brand-name inhalers to lower out‑of‑pocket costs for commercially insured and uninsured patients, but those savings programs generally exclude people with ...
The Advisory Committee on Immunization Practices (ACIP) voted 8–3 to remove the long-standing universal newborn hepatitis B (Hep B) birth‑dose recommendation, shifting to individual/shared decision‑ma...
Pfizer told lawmakers and the public that its decisions and communications about COVID‑19 vaccine timing were “driven by science and guided by the U.S.” regulatory process, saying it would respond to ...
For the 2025–2026 U.S. influenza season, federal guidance and product labeling show a clear shift to single‑dose, thimerosal‑free presentations: ACIP and CDC recommend that vaccines for children, preg...
There is no evidence in the provided reporting that any regulator‑approved supplement can modify the biological progression of frontotemporal dementia (FTD); multiple clinical reviews and advocacy gro...
There is no reporting in the documents provided that says Donald Trump personally invested capital into pharmaceutical companies or pharmaceutical-focused investment funds; the available sources descr...
For the 2025–26 U.S. season, most manufacturers are supplying single‑dose, thimerosal‑free prefilled syringes — specifically GSK’s Fluarix and Flulaval, Seqirus’s Afluria and Fluad, and CSL Seqirus’s ...
Available sources identify David E. Martin as a business founder and executive with a doctorate who built a career in patent analytics, drug development and corporate consulting rather than as a tradi...
State inhaler price‑cap laws and manufacturer assistance programs both lower what patients pay at the pharmacy, but they do so in different ways with different reach: state laws cap cost‑sharing acros...
The pivotal phase 3 ZOE-50 and ZOE-70 trials that supported SHINGRIX licensing were randomized, observer‑blind, placebo‑controlled studies — participants were assigned to receive two doses of the reco...
Shingrix (recombinant zoster vaccine, RZV) has a substantial published evidence base: pivotal phase III trials (ZOE‑50/70 and ZOE‑HSCT), regulatory reviews (FDA, EMA), company pooled datasets and post...
Clinical‑level patient data from many randomized statin trials have been shared with researchers through controlled‑access channels, but public reporting rarely lists trial names; an influential harmo...
Nine major drugmakers — Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche’s U.S. unit), Gilead Sciences, GSK (including ViiV), Merck, Novartis and Sanofi — agreed to sell selected me...
Yes — nine major pharmaceutical companies publicly agreed to lower the price of some of their medicines in deals announced by the Trump administration on Dec. 19, 2025, committing to “most-favored-nat...
GSK does not appear to make "all company-held data" for Shingrix publicly available for independent inspection; instead the company provides comprehensive datasets and analyses to regulators and publi...